Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report.
Autoimmunity
Covid-19 vaccine
Polymyalgia rheumatica
Systemic lupus erythematous
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
05
11
2021
accepted:
02
03
2022
revised:
01
03
2022
pubmed:
17
3
2022
medline:
4
5
2022
entrez:
16
3
2022
Statut:
ppublish
Résumé
The Pfizer-BioNTech COVID-19 vaccine has been authorized by the U.S. Food and Drug Administration as it demonstrated 95% effectiveness against the SARS-CoV-2 virus. Although the initial vaccine trials showed a favorable side effect profile, there have been concerns regarding activation of aberrant immune responses, triggering autoimmunity. This is a case report of a 68-year-old woman without history of autoimmune conditions, who presented to our emergency department 7 days after receiving the Pfizer-BioNTech COVID-19 vaccine. Her initial symptoms were suggestive of polymyalgia rheumatica, and she had nearly complete response to steroids. Interestingly, she later met criteria for classified systemic lupus erythematous given the development of inflammatory arthritis, positive ANA, and positive dsDNA. The temporal relationship of her symptoms that started 2 days after vaccine administration could suggest a possible association between the Pfizer-BioNTech COVID-19 and the development of systemic lupus erythematous.
Identifiants
pubmed: 35294664
doi: 10.1007/s10067-022-06126-x
pii: 10.1007/s10067-022-06126-x
pmc: PMC8924566
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1597-1601Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL007563
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, and C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615
Kanduc D, Shoenfeld Y (2020) Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res 68(5):310–313
doi: 10.1007/s12026-020-09152-6
A. Dotan, S. Muller, D. Kanduc, P. David, G. Halpert, and Y. Shoenfeld (2021) “The SARS-CoV-2 as an instrumental trigger of autoimmunity.,” Autoimmun. Rev., vol. 20, no. 4, p. 102792.
Justiz Vaillant AA, Goyal A, Bansal P, Varacallo M (2021) Systemic Lupus Erythematosus. in StatPearls. StatPearls Publishing, Treasure Island
Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80(1):14–25
doi: 10.1136/annrheumdis-2020-218272
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K (2020) The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 69(50):1922–1924
doi: 10.15585/mmwr.mm6950e2
“Vaccines and Related Biological Products Advisory Committee Meeting.” https://www.fda.gov/media/144434/download . Accessed May, 2021
King ER, Towner E (2021) A case of immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination. Am. J. Case Rep 22:e931478
doi: 10.12659/AJCR.931478
Radwi M, Farsi S (2021) A case report of acquired hemophilia following COVID-19 vaccine. J Thromb Haemost 19(6):1515–1518
doi: 10.1111/jth.15291
Renisi G, Lombardi A, Stanzione M, Invernizzi A, Bandera A, Gori A (2021) Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence? Int J Infect Dis 110:95–97
doi: 10.1016/j.ijid.2021.07.035
Repajic M, Lai XL, Xu P, Liu A (2021) Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav Immun Health 13:100217
doi: 10.1016/j.bbih.2021.100217
Kreuter A, Licciardi-Fernandez MJ, Burmann SN, Burkert B, Oellig F, Michalowitz AL (2021) Induction and exacerbation of subacute cutaneous lupus erythematosus following messenger-RNA or adenoviral-vector based SARS-CoV-2 vaccination. Clin Exp Dermatol 47(1):161–163
Kreuter A, Burmann SN, Burkert B, Oellig F, Michalowitz AL (2021) Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol 35(11):e733–e735
Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, Shoenfeld Y (2009) Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 18(13):1192–1197
doi: 10.1177/0961203309345732
Holmes AD, Abbasi OZ, Jacoby JL (2018) Systemic lupus erythematosus following meningococcal vaccination. Am J Emerg Med 36(1):170.e3-170.e4
doi: 10.1016/j.ajem.2017.10.020
Mason A, Anver H, Lwin M, Holroyd C, Faust SN, Edwards CJ (2021) Lupus, vaccinations and COVID-19: what we know now. Lupus 9612033211024356
Talotta R (2021) “Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to ‘potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol 224:108665
doi: 10.1016/j.clim.2021.108665
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663):1526–1529
doi: 10.1126/science.1093620
Weindel CG, Richey LJ, Bolland S, Mehta AJ, Kearney JF, Huber BT (2015) B cell autophagy mediates TLR7-dependent autoimmunity and inflammation. Autophagy 11(7):1010–1024
doi: 10.1080/15548627.2015.1052206
Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Fujimoto C, Kataoka S, Terada Y, Sano S (2014) Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol 66(3):694–706
doi: 10.1002/art.38298
Teijaro JR, Farber DL (2021) COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 21(4):195–197
doi: 10.1038/s41577-021-00526-x
Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25(3):383–392
doi: 10.1016/j.immuni.2006.08.010
Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB (2020) Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol 67:87–94
doi: 10.1016/j.coi.2020.10.014
Gadotti AC, de Castro Deus M, Telles JP, Wind R, Goes M, Garcia Charello Ossoski R, de Padua AM, de Noronha L, Moreno-Amaral A, Baena CP, Tuon FF (2020) IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res 289: 198171
Tang Y, Tao H, Gong Y, Chen F, Li C, Yang X (2019) Changes of Serum IL-6, IL-17, and complements in systemic lupus erythematosus patients. J Interferon Cytokine Res 39(7):410–415
doi: 10.1089/jir.2018.0169
Rovenský J, Tuchynová A (2008) Systemic lupus erythematosus in the elderly. Autoimmun Rev 7(3):235–239
doi: 10.1016/j.autrev.2007.11.014
Lazaro D (2007) Elderly-onset systemic lupus erythematosus. Drugs Aging 24(9):701–715
doi: 10.2165/00002512-200724090-00001
Department of health Pennsylvania. https://www.health.pa.gov/topics/disease/coronavirus/Vaccine/Pages/Dashboard.aspx . Accessed February, 2022